Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on March 27th. The trade occurred in the Representative’s “FIDELITY TRADITIONAL IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Novo Nordisk A/S (NYSE:NVO) on 3/27/2025.
• Purchased $50,001 – $100,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $15,001 – $50,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Purchased $1,001 – $15,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Sold $1,000,001 – $5,000,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/7/2025.
• Sold $15,001 – $50,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/6/2025.
• Sold $50,001 – $100,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $1.60 during trading hours on Tuesday, hitting $64.46. 5,940,900 shares of the stock were exchanged, compared to its average volume of 5,834,093. The stock’s 50-day moving average price is $77.02 and its two-hundred day moving average price is $92.75. Novo Nordisk A/S has a 12-month low of $59.32 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $289.27 billion, a price-to-earnings ratio of 19.59, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s payout ratio is 49.54%.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. increased its holdings in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after acquiring an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC increased its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC raised its holdings in Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock worth $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $86,000. Finally, Talbot Financial LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $4,066,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent research reports. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.